SCHEMBL852175

SCHEMBL852175

COc1ccc(B(O)OOCCO)cc1C12CC3CC(CC(C3)C1)C2

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RARA P10276 5/20 0.43
RARB P10826 4/20 0.43
RARG P13631 4/20 0.43
LMNA P02545 3/20 0.43
KMT2A Q03164 3/20 0.43
TDP1 Q9NUW8 2/20 0.43
MEN1 O00255 2/20 0.43
NR1I2 O75469 1/20 0.43
PGR P06401 1/20 0.43
HSPD1 P10809 1/20 0.43
GOT1 P17174 1/20 0.43
GLRA1 P23415 1/20 0.43
BLM P54132 1/20 0.43
HSPE1 P61604 1/20 0.43
HDAC11 Q96DB2 2/20 0.41
HDAC1 Q13547 1/20 0.41
HDAC7 Q8WUI4 1/20 0.41
HDAC8 Q9BY41 1/20 0.41
HDAC6 Q9UBN7 1/20 0.41
HDAC2 Q92769 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL852174 0.88 RARA (0.44) RARARARBRARGLMNAKMT2A
SCHEMBL404823 0.80 RARA (0.51) RARARARBRARGLMNAKMT2A
SCHEMBL31482681 0.80 RARA (0.51) RARARARBRARGLMNAKMT2A
SCHEMBL645476 0.77 RARA (0.44) RARARARBRARGLMNAKMT2A
SCHEMBL10014913 0.76 RARA (0.49) RARARARBRARGLMNAKMT2A
SCHEMBL7927692 0.74 RARA (0.40) RARARARBRARGLMNAKMT2A
SCHEMBL3318535 0.72 S1PR1 (0.53) RARARARBRARGLMNAKMT2A
SCHEMBL8424855 0.70 RARA (0.54) RARARARBRARGLMNAKMT2A
SCHEMBL8426196 0.70 RARA (0.54) RARARARBRARGLMNAKMT2A
SCHEMBL31150999 0.70 RARA (0.52) RARARARBRARGLMNAKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2139838-B1 A PROCESS FOR THE PREPARATION OF 6-[3-(1-ADAMANTYL)-4-METHOXYPHENYL]-2-NAPHTOIC ACID GRINDEKS JSC (LV) 2012-03-28 EP disclosed
US-20100160677-A1 PROCESS FOR PREPARATION OF 6-[3-(1-ADMANTYL)-4-METHOXYPHENYL]-2-NAPHTOIC ACID. JSC GRINDEKS (LV) 2010-06-24 US disclosed
EP-2139838-A2 A PROCESS FOR THE PREPARATION OF 6-Ý3-(1-ADAMANTYL)-4-METHOXYPHENYL-2-NAPHTOIC ACID Grindeks, a joint stock company (LV) 2010-01-06 EP disclosed
WO-2008080992-A2 A PROCESS FOR THE PREPARATION OF 6-[3-(1-ADAMANTYL)-4-METHOXYPHENYL-2-NAPHTOIC ACID KALVINSH IVARS (LV) 2008-07-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100160677-A1 PROCESS FOR PREPARATION OF 6-[3-(1-ADMANTYL)-4-METHOXYPHENYL]-2-NAPHTOIC ACID. ME1, CD274, PDCD1LG2 RARA 2036/4885RARB 2961/4885RARG 3424/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.